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MiR-212-3p functions as a tumor suppressor
gene in group 3 medulloblastoma via targeting
nuclear factor I/B (NFIB)
Naveenkumar Perumal1, Ranjana K. Kanchan1, David Doss2, Noah Bastola3, Pranita Atri1,
Ramakanth Chirravuri-Venkata1, Ishwor Thapa4, Raghupathy Vengoji1, Shailendra K. Maurya1, David Klinkebiel1,
Geoffrey A. Talmon5, Mohd W. Nasser1, Surinder K. Batra1 and Sidharth Mahapatra1,6*

Abstract
Haploinsufficiency of chromosome 17p and c-Myc amplification distinguish group 3 medulloblastomas which are
associated with early metastasis, rapid recurrence, and swift mortality. Tumor suppressor genes on this locus have not
been adequately characterized. We elucidated the role of miR-212-3p in the pathophysiology of group 3 tumors. First,
we learned that miR-212-3p undergoes epigenetic silencing by histone modifications in group 3 tumors. Restoring its
expression reduced cancer cell proliferation, migration, colony formation, and wound healing in vitro and attenuated
tumor burden and improved survival in vivo. MiR-212-3p also triggered c-Myc destabilization and degradation, leading to elevated apoptosis. We then isolated an oncogenic target of miR-212-3p, i.e. NFIB, a nuclear transcription factor
implicated in metastasis and recurrence in various cancers. Increased expression of NFIB was confirmed in group 3
tumors and associated with poor survival. NFIB silencing reduced cancer cell proliferation, migration, and invasion.
Concurrently, reduced medullosphere formation and stem cell markers (Nanog, Oct4, Sox2, CD133) were noted. These
results substantiate the tumor-suppressive role of miR-212-3p in group 3 MB and identify a novel oncogenic target
implicated in metastasis and tumor recurrence.
Keywords: 17p13.3, c-Myc, Group 3 medulloblastoma, miR-212-3p, Nuclear factor I/B
Introduction
Medulloblastoma (MB), the most common malignant
brain tumor of childhood, accounts for 20% of pediatric
central nervous system (CNS) neoplasms with annual
age-adjusted incidence ranging from 0.38 to 0.42 per
100,000 persons [32, 39]. Wingless-type (WNT), sonic
hedgehog (SHH), group 3, and group 4 are the classic
subgroups of MB with distinctive clinicopathologic and
molecular features [37]. The most aggressive tumors fall
into group 3 (non-SHH/WNT MB), which account for
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approximately 25–30% of all MB cases and belong to a
high-risk subgroup punctuated by haploinsufficiency
of 17p (20–50% incidence), c-Myc amplification (15–
20% incidence), and metastases close to or at diagnosis
(30–40%), all resulting in very poor prognosis with < 50%
5-year survivorship [3, 25, 38, 45]. Current treatment
regimens involve surgical resection followed by a combination of craniospinal radiation and multi-agent
chemotherapy, including vincristine, cisplatin, and either
cyclophosphamide or lomustine [40, 41]. Recent studies have implicated MB tumor-initiating (stem) cells in
evading chemotherapeutic regimens, facilitating recurrence [15, 31]. Recurrence can further reduce 5-year survival to < 10% [25, 43]. Thus, there is an urgent need to
understand group 3 MB pathobiology and key signaling
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pathways involved in disease progression and tumor
recurrence to provide a more accurate risk-adapted targeted treatment approach that can mitigate the dismal
survivorship of these patients.
Frequent cytogenetic events target the 17p13.3 locus
in group 3 MB and are associated with poor prognosis
[6, 7, 33]. Along this locus are multiple tumor suppressor genes and microRNAs (miRNAs), short nucleotide
noncoding RNAs capable of inhibiting expression of target genes by preventing translation or promoting degradation [2]. We recently reported the tumor-suppressive
properties of miR-1253, which lies on the terminal end
of this locus, in MB [24]. Similarly along this locus lies
miR-212-3p, a tumor suppressor gene in various cancers,
including lung cancer [19], hepatocellular carcinoma [5],
prostate cancer [56], and glioblastoma [28]. In colorectal
cancer [34] and nasopharyngeal carcinoma [20], miR212-3p targets MnSOD and Sox4, respectively, to prevent
metastasis and invasion. In breast cancer, miR-212-3p
regulates angiogenesis through Sp1 and VEGFA [27].
It can also sensitize cetuximab-resistant cells to growth
inhibition in head and neck squamous cell carcinoma by
targeting HBEGF [18]. Other oncogenic targets of miR212-3p include CTGF [5], Engrailed-2 [56], and SGK3
[28], which are involved in cancer cell proliferation,
migration, and invasion.
To date, no studies have examined the role of miR212-3p in MB pathogenesis. Given its location on a
highly afflicted chromosomal locus in high-risk MB, we
hypothesized that miR-212-3p possesses tumor-suppressive properties. Here, we have focused on thoroughly elucidating the anti-neoplastic properties of miR-212-3p in
group 3 MB and revealed a new oncogenic target of this
miR, Nuclear Factor I/B (NFIB).

Weishaupt et al., GSE124814) [9, 24, 52]. For Kaplan–
Meier Survival Analysis, we used the R2 database (Cavalli
et al., GSE85217) [3].

Methods
Human tissue samples and molecular subgrouping
of the MB tissues

Frozen and formalin-fixed paraffin-embedded (FFPE)
samples of normal cerebellum (pediatric = 12, adult = 5)
and pediatric MB specimens (WNT = 1, SHH = 7, group
3 = 10, group 4 = 14, unknown = 7) were collected from
the Children’s Hospital and Medical Center and the
University of Nebraska Medical Center, Omaha. Tumor
samples were sub-classified into four subgroups using
genome-wide DNA methylome analysis (Illumina Methylation EPIC 850 K bead arrays) as previously described
[24]. Normal cerebellum specimens were obtained at
autopsy. For expression profile of HDACs, EZH2, and
NFIB, we cross-analyzed our local MB dataset (Kanchan et al., GSE148390) with publicly available MB
datasets (Drusco et al., GSE62381; Roth et al., GSE3526;
Gilbertson et al., GSE37418; Kool et al., GSE10327; and

Cell lines and cell culture

All cell lines were authenticated using DNA methylation
profiling (New York University) and short tandem repeat
(STR) DNA profiling (UNMC). MB cell lines, i.e., D283,
D341, D425, were maintained in DMEM with 10–20%
FBS and 100 µg/mL penicillin/streptomycin; HDMB03
cells were cultured in RPMI with 10% FBS and 100 µg/
mL penicillin/streptomycin. Normal Human Astrocytes
(Lonza) were maintained using basal medium supplemented with growth factors. Cell lines were maintained
in 95% humidity, 37 °C, 5% CO2.
Reagents

MirVana™ miR-212-3p Mimic (Catalog: 4464066; Assay
ID: MC10340) and scramble negative control (Catalog:
4464059) were purchased from ThermoFisher Scientific. Silencing RNA for NFIB and EZH2 (Silencer™ PreDesigned siRNA (Catalog: 4392420); Assay ID: s9495 and
s4918, respectively) were obtained from ThermoFisher
Scientific. Tet-On-miR-212-3p lentiviral vector and
Tet3G (3rd generation) expression lentiviral vector (Vector ID:VB180123-1018bxq) were purchased from Vector
Builder Inc. Detailed reagent sections can be found in the
Additional file 1.
MicroRNA quantification

MiR-212-3p expression was quantified using TaqMan™
MicroRNA Reverse Transcription Kit and TaqMan™
Advanced miRNA Assay (Applied Biosystems). Isolated
total RNA was reverse transcribed using a specific stemloop primer for miR-212-3p (Catalog: 4427975, Assay
ID: 000515) and RNA U6B (Catalog: 4427975, Assay ID:
001093). After One-step TaqMan RT-PCR, miR-212-3p
was quantified and normalized to RNU6B using the
delta-delta Ct method.
DNA methylation profiling

Genome-wide DNA methylome analysis was performed
using the Illumina Methylation EPIC 850K bead arrays as
previously described [36]. Genomic DNA was extracted
from normal cerebellum and MB FFPE samples using
RecoverAll™ Total Nucleic Acid Isolation Kit (Invitrogen). Results are presented as percent methylation at
each CpG measured.
De-methylation studies

HDMB03 cells (3 × 105 in 6-well plates) were treated
with global de-methylating agent 5-AzaC (5 µM) (5-Aza2-deoxycytidine; Sigma). Following 96 h of incubation,
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miR-212-3p expression was analyzed using TaqMan RTPCR and presented as relative fold expression compared
to control.

assay); data were analyzed using the SOFTMAX PRO
software (Molecular Devices Corp.).
Colony formation assay

Chromatin immunoprecipitation assay

The chromatin immunoprecipitation (ChIP) assay was
performed with the Simplechip Enzymatic Chromatin IP
kit (CST, Catalog: 9003). Briefly, the digested cross-linked
chromatin (10 μg) was subjected to immunoprecipitation with 5 μg of anti-H3K27me3, anti-H3K4me3, antiH3K9me2, anti-H3K9Ac, or mouse/rabbit IgG control.
Purified ChIP DNA was amplified using specific primers
(Forward: 5′-GGAGTCCAGCTTCCTCTCCT-3′; and
Reverse: 5′-GCTCCTGGGGGTCTTCAC-3′) detecting
the CpG-enriched upstream promoter region of human
miR-212-3p. Results are presented as relative enrichment
normalized to respective input samples.
Stable inducible miR-212-3p expression system

Stable HDMB03 cells expressing inducible miR-212 with
luciferase reporter were generated using Tet-On Inducible lentiviral vector and Tet3G (3rd generation) lentiviral vector (VectorBuilder Inc.). Briefly, lentiviral particles
containing Tet3G vector were transduced with group
3 MB cell line (HDMB03 cells). Following hygromycin
antibiotic selection (100 µg/ml), stable HDMB03 cells
expressing Tet3G were transduced with lentiviral particles containing inducible miR-212 expression system.
The pure population of cells expressing inducible miR212 and luciferase reporter was double-selected using
puromycin selection (1 µg/ml) and mCherry positive cell
population sorting (flow cytometry).

After transfection/Dox treatment, MB cells (1 × 103
cells/well) were reseeded in 6-well plates and grown for
7–10 days in a humidified atmosphere (95% humidity)
at 37 °C and 5% CO2. Cells were washed, fixed with 2.5%
methanol and stained with 0.5% crystal violet. Cell staining was dissolved using 10% acetic acid and quantified by
measuring the absorbance at 590 nm.
Cell migration and invasion assay

For transwell migration/invasion assay, transfected/Dox
treated stable cells (5 × 105 cells) in serum-free media
were seeded in the upper chamber of an insert (8 mm
pore size; BD Bioscience) coated with Fibronectin (BD
Bioscience) or Matrigel (Invasion Chamber Matrigel
Matrix) followed by addition of a chemoattractant (10%
FBS in complete media) to the lower chamber. After
overnight incubation (16 h), cells that migrated/invaded
into the lower chamber were stained using Diff-Quik
Stain Set (Siemens Healthcare Diagnostics, Inc.); images
were captured using an EVOS FL Auto Imaging System
(Life Technologies). Results were quantitated by taking
an average cell count, measuring cell numbers from fourfield/images/well (10 × magnification).
Wound healing assay

Group 3 MB cells (3 × 105) were seeded overnight and
subsequently serum-starved for 4 h prior to transient
transfection using Lipofectamine 2000 (Invitrogen) for
6 h in serum-free media with miR-212-3p mimic (25 nM
and 50 nM) or scramble control (25 nM). Following incubation, fresh complete medium was added. For stable
induction , HDMB03 cells were treated with or without
Doxycycline (Dox, 500 ng/ml) in complete medium and
incubated at 37 °C, 5% CO2.

After transient transfection, cells (5 × 105 cells/well) were
plated in a 6-well plate, and upon reaching 80% confluence, a vertical scratch was made using a 10 µL pipette
tip. For stable cells, 3 × 104 cells/well were seeded in a
culture-insert (ibidi culture-insert 2 well), and after overnight incubation the culture-insert was removed and
washed with PBS to remove non-adherent cells. Fresh
growth medium (with and without Dox (500 ng/ml)) supplemented with 5% serum was added to the plates. The
wound closure area was photographed at denoted time
intervals using an EVOS FL Auto Imaging System (Life
Technologies). Quantitative measurements (% wound
closure) were determined by measuring three fields per
well.

Cell proliferation assay

Apoptosis and cell cycle analysis

MTT
[3-(4,
5-dimethylthiazol-2-yl)-2,
5-diphenyl2H-tetrazolium
bromide]
and
WST-1
[(4-[3-(4-Io dophenyl)-2-(4-nitro- phenyl)-2H-5tetrazolio]-1,3-benzene sulfonate)] assays were used
to determine cell viability in group 3 MB cells. After
transfection/Dox treatment, assays were performed at
24–96 h; absorbances were measured using a microplate reader at 570 nm (MTT assay) and 440 nm (WST-1

Annexin-V/Cy™5 (BD Biosciences) and propidium iodide
(PI) (Roche Diagnostics) were used to measure apoptosis
and cell cycle profile as previously described [24]. Briefly,
miR-212-3p mimic or scramble control transfected cells
were incubated for 96 h. Following incubation, cells were
washed and resuspended in calcium-binding buffer consisting of Annexin-V/Cy™5 and PI (apoptosis assay) or
fixed with 70% ethanol and stained with PI (cell cycle

MiR-212-3p expression restoration
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analysis). Stained cells were analyzed using a FACS
Canto™ Flow cytometer (BD Bioscience).
Western blotting

Protein lysates (30 µg/lane) were separated on 10% SDSPAGE gels and transferred to PVDF membrane. Following blocking, target proteins were detected by probing
overnight at 4°C with antibodies against: NFIB, Bin1 and
p19ARF (Abcam); PARP, cleaved PARP, cleaved caspase-3,
caspase-3, cyclin D1, CDK4, CDK6, p-Akt-ser473,
β-catenin, and CD133 (Cell Signaling Technologies);
and total Akt, p-Erk and ERK (Santa Cruz Biotechnology). Then, membranes were washed and incubated with
anti-mouse/rabbit IgG secondary antibody (Invitrogen)
conjugated with horseradish peroxidase (HRP) at room
temperature. Specific proteins were visualized using an
enhanced chemiluminescence detection reagent (Pierce;
ThermoFisher Scientific, Inc.).
MiR-212 target prediction

MiRNA target prediction databases, i.e., Targetscan
(http://www.targetscan.org) and mirDIP (http://ophid.
utoronto.ca/mirDIP/) were used to determine the putative targets of miR-212-3p. Genes that were downregulated upon miR-212-3p restoration in HDMB03 (RNA
sequencing analysis) were compared against them.
Targets were chosen based on log2 fold change < −1
and p < 0.05, yielding 37 common gene targets for
miR-212-3p.
Dual-luciferase reporter assay

Primers for 3′UTR-NFIB (Forward: 5′-GCTTGCTAG
CTACACACCAGGGT-3′; and Reverse: 5′-TAGCAG
TATAGGCTGGATA-3′) were designed using NCBIPrimer-BLAST tool (https://www.ncbi.nlm.nih.gov/
tools/primer-blast/) and purchased from Eurofins. Following PCR amplification of NFIB (3′UTR), mutations
were created within the seed sequence of NFIB. The
resulting 3′UTR-Wild and 3’UTR-Mutant genes were
inserted into the XbaI restriction site of pGL3-control
vector (Promega) expressing firefly luciferase. Dualluciferase reporter assay was performed on HDMB03
cells (3 × 105 cells/well) seeded in 12-well plates. Following overnight incubation, cells were co-transfected
with 3’UTR-wild-pGL3/3′UTR-Mutant-pGL3 plasmid,
pRL-TK plasmid (Promega) expressing Renilla luciferase
(internal control), and miR-212-3p mimic/scramble control for 48 h. Luciferase activity was then measured using
the Dual-Luciferase Reporter Assay System (Promega)
with a Luminometer (Biotek). Results are presented as
Luciferase activity (%), where firefly luciferase activity
was normalized to Renilla luciferase activity (internal
control) for each transfected sample.
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Immunohistochemistry

Unstained tissue slides (3 µm) were deparaffinized in
xylene, rehydrated in a series of alcohol dilutions, and
heated in citrate buffer (pH 6.2) for 20 min. Following
antigen retrieval, slides were incubated with blocking
buffer (Horse serum, Vector Labs) for 60 min at room
temperature. Subsequently, anti-NFIB (1:200), anti-cMyc (1:200), anti-Ki-67 (1:200), or anti-Cleaved Caspase
3 (1:200) primary antibody was added and incubated
overnight at 4°C. After PBS wash, slides were incubated
with secondary antibody (goat anti-rabbit/mouse conjugated with horseradish peroxidase) for 60 min at room
temperature. Detection was performed with DAB Peroxidase Substrate Kit (Vector Labs) followed by counterstaining with hematoxylin. Sections were visualized
under EVOS FL Auto Imaging System (Life Technologies). Then the tissues were scored according to the
intensity of the dye color and the number of positive cells.
The method for IHC score was as follows: 0, negative;
1, < 25% positive tumor cells; 2, 25–50% positive tumor
cells; 3, 50%-75% positive tumor cells; and 4, > 75% positive tumor cells. Dye intensity was graded as 0 (no color),
1 (light yellow), 2 (light brown), or 3 (brown). Composite scores were derived from product of staining intensity
and % positive cells (0–12).
Sphere formation assay

For primary and secondary spheres, HDMB03 cells
(4 × 105 cells/well) were seeded in Ultra-Low Attachment
6-well plates (Corning™ Costar™ Microplates). Cells
were maintained in stem cell media (DMEM/F12, 2%
B27, 20 ng/mL bFGF, 20 ng/mL EGF, 40 U/ml penicillin,
and 40 μg/ml streptomycin), and incubated for 10 days
at 37 °C, 5% CO2. Following incubation, primary spheres
were dissociated into single cell suspension, reseeded,
and allowed to grow for another 10 days to form secondary spheres. Spheres having diameter larger than 50 μm
were counted.
Orthotopic medulloblastoma mouse model

All experimental animal procedures were approved
by the Institutional Animal Care and Use Committee
(IACUC). Briefly, four to six-week-old NSG (NOD-scid
Il2rgnull) mice were anesthetized using ketamine and
xylazine (i.p.) and transferred to a stereotactic frame
(Stoelting Co, IL, USA). Hamilton syringe (26-gauge needle) with stable Tet-on miR-212 inducible HDMB03 cells
(1.0 × 105 cells/5 µl of PBS) was implanted into the cerebellum (2-mm lateral and 2-mm posterior to lambda,
and 2.7-mm deep from the surface of the skull), with a
speed of 1 µl/min. Needle was removed after 5 min.
After surgery, tumor growth, based on total photon flux,
was measured using an IVIS Spectrum imaging system
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(Caliper life sciences; PerkinElmer, MA, USA). Based
on tumor size, mice were randomized into two groups
(i) control and (ii) DOX treatment group; doxycycline
(2 mg daily through oral gavage) induced expression of
miR-212-3p. Tumor growth was monitored using an IVIS
Spectrum imaging system. On appearance of first neurological symptoms (as per IACUC guidelines), animals
were euthanized. Brains were fixed for analysis.

in CSF samples of patients with MB (NC = 14 vs.
MB = 15; GSE62381), revealing reduced expression
compared to normal (Fig. 1A (i)). Subsequent expression examination in our local pediatric MB cohort
(GSE148390) revealed specific downregulation in group
3 (n = 9) and group 4 (n = 13) MB tumors (Fig. 1A (ii)).
We cross validated these results using RT-PCR, noting
near-abrogation of expression of miR-212-3p in group
3 MB (n = 10) and group 4 MB samples (n = 12) compared to pediatric cerebellum (n = 10) (Fig. 1B). In vitro,
we recapitulated these findings in a panel of MB cell lines
with characteristic high-risk features, including i17q
and c-Myc amplification (group 3 MB—D341, D425,
HDMB03; group 3/4 MB—D283). These were in stark
contrast to normal human astrocytes (NHA) and an SHH
MB-type cell line, i.e. Daoy, with high expression of miR212-3p (Fig. 1C). These results substantiated a decreasedto-absent expression of miR-212-3p specific to group 3
and 4 MB tumors and cell lines. We thus chose to focus
the rest of our study on group 3 tumors.
To elucidate a mechanism for expression silencing, we
studied epigenetic mechanisms, i.e. hypermethylation
vs. histone modification. We initially performed DNA
methylation profiling in our group 3 MB patient samples
(n = 6) but found no perturbation to the methylation of
the miR-212-3p promoter region when compared to
normal pediatric cerebellum (n = 4). In vitro, these findings were supported by a lack of expression restoration
in HDMB03 cells treated with the global demethylating
agent, 5-AzaC (5 µM, 96 h) (Additional file 2: Fig. S1B).
Several studies have linked aberrant methylation
and acetylation of key histones involved in chromatin
structure, including H3K4 and H3K27, with enhanced
disease aggressiveness mainly in group 3 and group 4
tumors [10, 22]. Moreover, studies targeting histone deacetylases (HDACs) have revealed growth inhibition of
MYC-driven medulloblastomas [11, 12, 42]. Thus, we
shifted our focus to histone modification-mediated epigenetic regulation. Our initial in silico analysis of HDAC
expression revealed high expression of HDAC 1, 3, 5, 9,

Statistical analysis

All experiments were conducted in triplicate. Values are
presented as mean ± SD. Statistical analyses were performed using Prism 7.0b (GraphPad Software). For data
normalization, control group was set at “1” and experimental groups were represented as fold-change compared to control with error bars reflecting deviation from
mean triplicate measurements; statistical analyses were
conducted prior to normalization. Differences between
groups were compared using a two-tailed, unpaired Student’s t-test, Mann–Whitney U test or one-way analysis of variance followed by a least significant difference
post hoc test. Statistical significance was established at
*p < 0.05, **p < 0.01, and ***p < 0.001.

Results
MiR-212-3p expression is epigenetically silenced
by histone modifications in group 3 MB

Group 3 tumors belong to a high-risk subgroup punctuated by haploinsufficiency of 17p (20–50% incidence),
c-Myc amplification (15–20% incidence), and metastases
proximate to diagnosis (30–40%), all resulting in < 50%
5-year survivorship [3, 25, 38, 45]. Our local MB cohort
recapitulated these distinguishing findings in group 3
tumors, with a very high frequency of haploinsufficiency
of 17p (90%), c-Myc amplification (40%), metastasis proximate to diagnosis (30%), and low 5-year overall survival
(40%), and was comparable to a larger MB dataset [3]
(Additional file 2: Fig. S1A(i) and (ii)).
To explore the regulation of miR-212-3p in MB, we first
conducted an in silico expression analysis of miR-212-3p

(See figure on next page.)
Fig. 1 Expression and epigenetic regulation of miR-212-3p in group 3 MB tumors. A MiR-212 expression analysis by RNA Sequencing using (i)
a publicly available MB dataset (NC n = 14; MB n = 15; Drusco et al., GSE62381) and (ii) a local MB cohort (adult NC n = 4; pediatric NC n = 10;
SHH n = 5; group 3 MB n = 9; group 4 MB n = 13; Kanchan et al., GSE148390). B Results validated in local MB cohort by RT-PCR (NC n = 10; G3MB
n = 10; G4MB n = 12). C RT-PCR analysis of miR-212 expression in classic MB cell lines (group 3: D341, D425, HDMB03; group 3/4: D283; SHH: Daoy)
compared to normal human astrocytes (NHA). D In silico expression of HDACs and EZH2 to investigate epigenetic modulation of miR-212 (NC
n = 10; group 3 MB n = 7; Kanchan et al., GSE148390). E ChIP-qRT-PCR analysis in group 3 MB cells with deregulated histone modifications in the
promoter region of miR-212-3p. ChIP grade histone mark antibodies to H3K27me3, H3K9me2 and H3K9Ac used; IgG antibody as negative control;
Daoy cells with high intrinsic miR-212-3p expression served as an additional control. F MiR-212-3p expression restoration after treatment with
pan-HDAC inhibitors (TSA, 100 nM; Belinostat, 1 µM; and Vorinostat, 1 µM) and with siRNA-EZH2 (20 nM) in HDMB03 cells. Increase in acetylated
α-tubulin levels demonstrated pan-HDAC inhibitor activity in HDMB03 cells. β-actin served as an internal control. Data presented as mean ± SD
from experiments done in triplicate and analyzed using Mann–Whitney U test (A and D) or Student’s t-test (B, C, E and F); *p < 0.05, **p < 0.01,
***p < 0.001. NC, normal cerebellum; MB, medulloblastoma; G3MB, group 3 medulloblastoma; G4MB, group 4 medulloblastoma
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and EZH2 in both our local cohort (group 3 MB n = 7;
GSE148390) and in a larger group 3 MB cohort (group
3 MB n = 233; GSE124814) when compared to normal
cerebellum (n = 10 and n = 291, respectively) (Fig. 1D

and Additional file 2: Fig. S1C). To confirm a specific pattern of histone modification in the predicted miR-212-3p
transcription start-site (TSS) in group 3 cells, histone
mark patterns of group 3 MB cell lines (HDMB03 and
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D425) were compared with normal human astrocytes
(NHA) and an SHH MB cell line (Daoy). CHIP-qRT-PCR
analysis revealed important differences in the methylation status of H3K27 and H3K9 and in the acetylation
status of H3K9 in group 3 MB cell lines compared to
NHA and Daoy cells (Fig. 1E). Specifically, HDMB03 and
D425 cells, with baseline reduced miR-212-3p expression, showed enriched methylated H3K27 and H3K9,
with a concomitant decrease in acetylated H3K9, compared to NHA. In contrast, Daoy cells, with high intrinsic
miR-212-3p expression, were hypomethylated at H3K27
and showed no change to the acetylation pattern of H3K9
compared to NHA. Consequently, treatment of HDMB03
and D425 cell lines with pan-HDAC inhibitors (TSA,
100 nM; Belinostat, 1 µM; Vorinostat, 1 µM) substantially
increased miR-212-3p expression compared to vehicle
control (Fig. 1F and Additional file 2: Fig. S1D). Silencing
EZH2 expression (siRNA-EZH2, 20 nM) accomplished
the same (Fig. 1F). Together, these findings strongly
implicated a unique pattern of histone modification as
a silencing mechanism for miR-212-3p in group 3 MB
tumors.

c-Myc phosphorylated at serine 62 increases stability
leading to tumor aggressiveness, while phosphorylation at threonine 58 destabilizes the protein, leading to
ubiquitin-mediated degradation and subsequent cellular
apoptosis [14, 23]. Transient transfection of HDMB03
cells with miR-212-3p resulted not only in a reduction
in total c-Myc protein but also a concomitant increase
in the ratio of phosphorylated T58 to phosphorylated
S62 (Fig. 3A). Concurrently, the active upstream kinases
responsible for c-Myc stabilization via phosphorylation
at S62, i.e. p-Erk and p-Akt [46], were both significantly
decreased in these cells (Fig. 3A). In miR-212-3p stablyexpressing HDMB03 cells, c-Myc expression was almost
completely abrogated, with consequent reductions in
both phosphorylated species of c-Myc. As prior, p-AKT
and p-ERK were also significantly reduced. Together,
these data purported a c-Myc deregulatory function for
miR-212-3p. Of note, in gastric cancer, c-Myc has been
revealed as a direct target of miR-212 [55].
We then focused on progression through the cell cycle,
given the destabilization of c-Myc and a reduced proliferative phenotype noted in the presence of miR-212-3p.
Not surprisingly, we revealed arrest in transientlytransfected miR-212-3p mimic-treated cells (25 nM and
50 nM) at the G0/G1 phase of the cell cycle in HDMB03
cells (Fig. 3B). We confirmed the phase of arrest using
Western blotting, which showed decreased expression of
the complementary checkpoint markers, CDK4, CDK6,
and cyclin D1 (Fig. 3A and C). In support, hierarchical clustering and pathways analysis revealed that miR212-3p expression restoration led to the enrichment of
gene clusters (4, 5, 8) involved in the regulation of cell
cycle phase (Additional file 4: Fig. S3A and B, and Additional file 5: Table S1).
We concluded our study of the anti-neoplastic properties of miR-212-3p by analyzing its effect on cancer cell apoptosis. We first examined the expression of
c-Myc binding partners that signal for apoptosis, i.e.
Bin-1 and p19ARF, along with various pro-apoptotic
proteins. MiR-212-3p restoration in HDMB03 cells significantly increased expression of Bin-1 and p19ARF concurrent with rises in cleaved PARP and cleaved caspase
3 (Fig. 3D). These results were validated using Annexin
V-cy5/PI staining, demonstrating a two- and threefold
increase in late and early apoptosis, respectively, compared to control (Fig. 3E).
Taken together, our results identified an apoptotic
mechanism for miR-212-3p, either by altering c-Myc
phosphorylation states to destabilize c-Myc, by reducing the total c-Myc expression, and/or by increasing the
expression of its pro-apoptotic binding partners. In parallel, miR-212-3p played a role in cell cycle arrest at the
G0/G1 phase.

MiR-212-3p expression restoration inhibits group 3 MB cell
growth and proliferation

To highlight the tumor-suppressive properties of miR212-3p in group 3 MB, we employed two methods to
restore miR-212-3p expression, i.e. by transient transfection with miR-212-3p mimic or by Dox-inducible stable expression in group 3 MB cell lines. With successful
miR-212-3p expression restoration (Fig. 2A), cancer cell
growth and proliferation were significantly impacted
in a time- and dose-dependent manner (Fig. 2B). Similarly, colony formation, transwell migration, and wound
closure assays all recapitulated this anti-neoplastic phenotype with reduced colonies, cellular migration, and
wound closure, respectively (Fig. 2C–E). Although overexpressing miR-212-3p in Daoy cells decreased cell
proliferation and colony formation, a dose- and timedependent effect was absent. Instead, growth inhibitory
effects seemed to plateau within 24 h and with a 25 nM
concentration of miR-212-3p, suggesting that SHH cell
lines do not experience the same growth inhibition as
group 3 cell lines do (Additional file 3: Fig. S2A–C).
These data provided compelling in vitro evidence for the
tumor-suppressive properties of miR-212-3p, expressly in
group 3 MB.
MiR-212-3p induces cell cycle arrest and destabilizes c-Myc
to favor apoptosis in group 3 MB

Myc amplification is a cardinal high-risk feature of group
3 MB, and its phosphorylation status influences downstream tumor phenotype [43, 44]. More specifically,
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Fig. 2 Effect of miR-212-3p expression on the neoplastic potential of group 3 MB cancer cells. A MiR-212-3p expression restoration via transient
(HDMB03 and D425) and Dox inducible (HDMB03) systems by RT-PCR. B Cell proliferation assays (MTT and WST-1) showing significantly reduced
proliferative potential with both transient and stable expression of miR-212-3p in a time- and dose-dependent manner in group 3 MB cells. Similar
growth-restrictive properties demonstrable via colony formation and transwell migration (C and D), and wound healing assays (E) with both
transient and stable expression of miR-212-3p in HDMB03 cells. Data presented as mean ± SD from experiments done in triplicate and analyzed
using Student’s t-test; *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar: 100 μm
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NFIB is a downstream target of miR-212-3p

To identify oncogenic targets of miR-212-3p, we started
with the targets that are common to miRNA target prediction databases (TargetScan and mirDIP) and that are
significantly downregulated (Log2 fold change < −1.0,
p < 0.05) by miR-212-3p expression restoration in
HDMB03 cells (Fig. 4A). This comparison revealed 37
putative targets whose expression and associated pathways were studied in two group 3 MB patient cohorts
(Fig. 4B (i) and (ii), and Additional file 6: Fig. S4A and B).
Out of the 37 common targets, fourteen were upregulated in group 3 MB (summarized in Additional file 7:
Table S2). NFIB was chosen for further study based on
the following characteristics that bestow a high likelihood
of oncogenic potential in group 3 MB: (i) there are two
conserved binding sites for miR-212-3p on the 3′UTR
of NFIB mRNA (TargetScan); (ii) expression of NFIB
was significantly increased across multiple MB datasets (Fig. 4C); (iii) and significantly elevated across MB
subgroups (Fig. 4D and Additional file 6: Fig. S4C); (iv)
Kaplan–Meier Survival Analysis showed poor survival
in high-expressing patients (Cavalli et al., GSE85217, via
R2 database) [3] (Fig. 4E); (v) high expression was shown
in a panel of group 3 MB cell lines (HDMB03, D425, and
D341) compared to NHA (Fig. 4F); and (vi) immunohistochemical staining of NFIB in group 3 MB tissues (n = 9)
revealed intense nuclear staining when compared to normal cerebellum (n = 8) (Fig. 4G). We further validated
this target by the dual-luciferase assay (Fig. 4H) and
showed significant attrition in miR-212-3p mimic treated
HDMB03 cells at the transcription (Fig. 4I) and translation levels (Fig. 4J). In this manner, we identified NFIB as
an oncogenic target of miR-212-3p.
NFIB possesses oncogenic potential in group 3 MB cancer
cells
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that recognize palindromic sequences on various promoters capable of activating transcription and replication
throughout organ development [16, 49]. An oncogenic
role for NFIB has been shown in triple-negative breast
cancer (TNBC), small cell lung cancer (SCLC), colorectal and gastric cancers, and melanoma by enhancing
tumor growth, epithelial-mesenchymal transition (EMT),
migration, and invasion [13, 29, 30, 47, 53].
With this prior evidence, we elucidated the oncogenic
role of NFIB in group 3 MB cancer cells by studying the
effect of silencing expression on proliferation, transwellmigration, and invasion. Silencing NFIB in HDMB03
cells transiently resulted in a significant reduction in cell
proliferation up to 48 h (Fig. 5A). Transwell migration
and invasion assays demonstrated similar reductions in
cell migration and invasion (Fig. 5B).
Mechanistically, NFIB overexpression has been shown
to increase chromatin accessibility, promote the expression of pro-metastatic genes, and drive metastasis in
SCLC tumors [8, 47, 54]. Studies in SCLC have also
revealed NFIB as a downstream target of c-Myc, which
directly regulates its expression and contributes to tumor
aggressiveness and rapid metastases [35]. However, we
have shown that miR-212-3p has a deregulatory effect on
c-Myc. To delineate if NFIB inhibition plays a role in Myc
regulation, we silenced NFIB in group 3 MB cells using
transient siRNA-NFIB treatment. As with miR-212-3p
stable expression, NFIB silencing decreased total c-Myc
levels with a concomitant decrease in phosphorylation of
c-Myc at S62 and T58; moreover, upstream c-Myc regulators i.e. p-Akt and p-Erk, were also significantly reduced
(Fig. 5C).
Given the direct inhibitory effect of miR-212-3p on
c-Myc and NFIB’s promoting role in metastasis, we
sought to study the effect of the miR-212-3p/NFIB axis

Nuclear Factor I/B (NFIB) belongs to the nuclear factor
I (NFI) family of transcription and replication proteins

(See figure on next page.)
Fig. 3 Effect of miR-212-3p expression on c-Myc regulation, cell cycle progression and apoptosis in group 3 MB cancer cells. A Western blotting
analysis of c-Myc stimulatory signals showing a shift in c-Myc phosphorylation states from serine-62 (active form) to threonine-58 (inactive form)
in miR-212-3p transiently transfected HDMB03 cells. In dox-induced stable miR-212 expression, total c-Myc was reduced. Upstream activators of
c-Myc, i.e., p-Akt and p-Erk, also destabilized upon miR-212-3p restoration. B Cell cycle analysis by propidium iodide (PI) staining showing arrest at
G0/G1 phase in miR-212-3p transiently transfected HDMB03 cells. C Western blotting analysis demonstrating reduced expression of G0/G1 regulatory
checkpoint proteins, CDK4, CDK6, and cyclin D1, but not CDK2, in miR-212-3p transiently transfected HDMB03 cells. D Elevated expression of
pro-apoptotic binding partners of c-Myc, i.e., Bin-1 and p19ARF, concurrent with expression of apoptotic proteins (cleaved PARP and cleaved
caspase-3) in miR-212-3p restored HDMB03 cells. E Annexin-Cy5 and PI staining confirming increased apoptosis (early and late) in miR-212-3p
transiently transfected HDMB03 cells compared to scramble control. β-actin served as an internal loading control. Data presented as mean ± SD
from experiments done in triplicate and analyzed using Student’s t-test; *p < 0.05, **p < 0.01, ***p < 0.001
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on cancer stem cell (CSC) maintenance and self-renewal.
We first analyzed the expression of stem cell markers in miR-212-3p stably-expressing and NFIB-silenced
HDMB03 cells. RT-PCR and Western blotting analyses
revealed concurrent de-regulation in the expression of
several stem cell markers, including CD133, β-catenin,
Sox-2, Oct-4, and Nanog (Fig. 5D and E). CSCs selfrenewal ability was further assessed through tumor
sphere-forming assay. Again, in both NFIB-silenced and
miR-212-3p stably-expressing cancer cells, substantially
decreased numbers of spheres were noted (Fig. 5F and
G). These results further elucidated the anti-neoplastic
properties of miR-212-3p with its inhibitory role on CSC
maintenance and implicated NFIB as a strong oncogenic
target of miR-212-3p in group 3 tumors.

developed tumors with substantially reduced staining
for Ki-67, c-Myc, and NFIB with a concomitant increase
in staining for cleaved caspase-3 (Fig. 6F). These in vivo
results substantiated the anti-proliferative, pro-apoptotic, and tumor-suppressive properties of miR-212-3p
(Fig. 6G) in group 3 MB tumors.

Restoration of miR-212-3p expression inhibits the growth
of orthotopic group 3 MB tumors

To determine the role of miR-212-3p in group 3 MB
tumor growth and progression in vivo, we implanted
stable miR-212-inducible HDMB03 cells into the cerebellum of mice as detailed in Fig. 6A. MiR-212-3p
expression was restored in mice via daily doxycycline
supplementation (oral gavage). At day 16, Dox-fed mice
showed significant reduction in tumor growth compared
to control (Fig. 6B and C). Moreover, Kaplan-Meier survival analysis revealed significantly higher survival in the
Dox-fed group compared to control (Fig. 6D). Tumor histology revealed smaller tumor margins in Dox-fed mice
compared to control (Fig. 6E). In addition, Dox-fed mice

Discussion
Haploinsufficiency of chromosome 17p bestows a highrisk phenotype upon group 3 tumors [3, 25, 45]. Several
loci populated by tumor suppressor genes can be found
within the afflicted short arm. Studies have linked few
genes residing on the terminal locus (17p13.3) with MB,
such as ROX/MNT [7] or HIC1 [51]. None have studied
microRNAs on this locus. We previously elucidated the
anti-neoplastic properties and oncogenic targets of miR1253, a microRNA found on the terminal part of this
locus, in MB [24]. In the present study, we have described
the tumor-suppressive properties of miR-212-3p in group
3 MB; we have additionally identified a target with strong
oncogenic potential.
An initial in silico analysis of a publicly available MB
dataset revealed significantly reduced expression for
miR-212-3p compared to normal. These findings were
specifically recapitulated in non-SHH/WNT tumors both
in pediatric samples (ex vivo) and in classic MB cell lines
(in vitro). Focusing on the higher risk group 3 tumors,
we sought a mechanism for miR-212-3p silencing. In
many cancers, microRNAs undergo epigenetic silencing
via hypermethylation along CpG islands or chromatin

(See figure on next page.)
Fig. 4 Isolating oncogenic targets of miR-212-3p in group 3 MB tumors. A Venn diagram showing 37 common targets between miRNA target
prediction databases (Targetscan and miRDip) and genes downregulated (Log2 fold change < − 1.0, p < 0.05) in miR-212 expressing HDMB03 cells
(via RNA sequencing analysis). B Expression heat map of the 37 identified targets of miR-212 in two MB data sets, (i) local (pediatric cerebellum
n = 10; group 3 MB n = 7; Kanchan et al., GSE148390) and (ii) larger meta-dataset (normal cerebellum n = 291; group 3 MB n = 233; Weishaput et al.,
GSE124814). C Elevated expression of NFIB across MB datasets (NC n = 9, Roth et al. 2008; MB1 n = 76, Gilbertson et al. 2012; MB2 n = 223, Pfister
et al. 2017; MB3 n = 57, Delattre et al. 2012; MB4 n = 62, Kool et al. 2009). D Elevated NFIB expression across subgroups within local MB cohort
(pediatric NC n = 10; SHH n = 6; group 3 n = 7; group 4 n = 12; Kanchan et al., GSE148390). E Kaplan–Meier Survival Analysis demonstrating poor
survival in high NFIB-expressing MB patients (n = 542) compared to low-expressing patients (n = 70) (Cavalli et al., GSE85217). F Western blotting
showing significantly increased expression of NFIB in classic group 3 MB cell lines (HDMB03, D425, and D341). G Immunohistochemical staining of
NFIB showing intense nuclear expression in group 3 MB patient samples (n = 9) when compared to normal cerebellum (n = 8). H Dual-luciferase
assay confirming NFIB as a direct target of miR-212-3p. I RT-PCR and J Western blotting analysis showing significantly decreased expression of NFIB
in miR-212-3p transiently transfected HDMB03 cells. β-actin served as an internal loading control. Data presented as mean ± SD from experiments
done in triplicate and analyzed using Mann–Whitney U test (C and D) or Student’s t-test (E, G, and H); *p < 0.05, **p < 0.01, ***p < 0.001. Scale bar:
100 μm. NC, normal cerebellum
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rearrangement through histone modifications [24, 26].
Methylation profiling in high-risk tumors showed no differences in methylation pattern of the miR-212-3p locus
between tumors and normal tissue. Contrarily, histone
modifications at critical lysine residues within miR212-3p provided compelling evidence for an epigenetic
silencing mechanism. More specifically, increased methylation at H3K27 and H3K9 and a concomitant decline in
acetylation of H3K9 was shown by ChIP-RT-PCR. Either
treatment with HDAC inhibitors or EZH2 silencing reliably restored miR-212-3p expression. Together, these data
revealed miR-212-3p silencing in group 3 tumors and
assigned an epigenetic mechanism via histone modifications. Our findings aligned with prior reported patterns
of miR-212-3p epigenetic silencing in lung cancer [19].
Restoring miR-212-3p expression in group 3 MB
cells by either transient transfections or stable induction resulted in a cadre of anti-neoplastic effects. First,
cancer cell proliferation, wound healing, migration,
and colony formation were significantly reduced. Subsequently, cell proliferative markers, p-Akt and p-Erk,
were downregulated in miR-212-3p restored cells, eventually leading to cell cycle arrest (G0/G1 cell cycle phase)
with dysregulated expression of checkpoint regulatory
kinases, CDK4, CDK6, and cyclin D1. Next, we revealed
regulatory effects of miR-212-3p on c-Myc phosphorylation states, with transient expression resulting in a shift
in phosphorylation patterns from S62 (active, favoring
proliferation) to T58 (inactive, favoring apoptosis), and
stable expression leading to a near-abrogation in total
c-Myc expression. Of note, p-Akt and p-Erk, which were
downregulated by both transient and stable miR-212-3p
expression, are upstream kinases that phosphorylate
c-Myc at S62, rendering it resistant to degradation [14,
23]. Moreover, in miR-212-3p-expressing cells, key apoptotic binding partners of c-Myc, p19ARF and Bin-1, were

elevated in tandem with cleaved PARP and cleaved caspase‐3, resulting in a high apoptotic signal in cancer cells.
As prior, our results aligned with studies on miR-212-3p
in colorectal cancer [34], nasopharyngeal carcinoma
[20], and lung cancer [21] where similar effects were
seen on cancer cell proliferation, migration and invasion, cell cycle arrest, and apoptosis. Given the high association between c-Myc amplification and poor prognosis
in group 3 MB [3, 45], our data suggested a plausible
mechanism contributing to high-risk MB aggressiveness,
wherein silencing miR-212-3p may lift its regulation of
c-Myc, allowing for unchecked Myc-driven signaling.
We next identified an oncogenic target of miR-212-3p
using in silico, ex vivo, and in vitro approaches. In so
doing, we revealed Nuclear Factor I/B (NFIB), a transcription factor that can bind to specific overlapping
DNA repeat sequences (5′-TTGGCNNNNNGCCAA-3′)
throughout the genome to activate transcription and replication, most notably in normal lung and brain development [16, 49]. In fact, the 14 target genes of miR-212
isolated via high-throughput analyses of independent MB
datasets seemed most intricately involved in these processes (Additional file 6: Fig. S4B). Given the association
of high NFIB expression in group 3 tumors with poor
survival, we showed that silencing NFIB expression dramatically decreased cancer cell proliferation, migration,
and invasion in vitro. Similar effects have been shown for
NFIB in gastric cancers [53], TNBC [29], SCLC [47], and
colorectal cancer [30]. In colorectal cancer, melanoma,
and gastric cancers, overexpression of NFIB was associated with epithelial-mesenchymal transition (EMT),
migration and invasion [13, 30, 53]. In melanoma, specifically, NFIB-targeted upregulation of EZH2 led to
the epigenetic silencing of MITF, promoting a highly
invasive phenotype [13]. In SCLC, NFIB overexpression
cooperated with Rb/p53 deletion to increase chromatin

(See figure on next page.)
Fig. 5 Effect of NFIB silencing on cancer cell phenotype in group 3 MB. A Transient silencing of NFIB (siRNA-NFIB, 20 nM) showing significant
reduction in HDMB03 cell viability compared to siRNA-control cells. B Transwell migration/invasion assay recapitulating the same with decreased
migrating and invading cells in siRNA-NFIB-treated cells compared to control. C Western blotting analysis of c-Myc showing reduction in total
c-Myc, p-S62, p-T58 and reduction in upstream activators of c-Myc, i.e., p-Akt and p-Erk. RT-PCR and Western blotting analyses demonstrating
reduced stem cell markers, i.e. Nanog, Oct4, Sox2, CD133 and β-catenin, in D siRNA-NFIB-treated HDMB03 cells and E Dox-treated stably-expressing
miR-212-3p HDMB03 cells. Medullosphere assays demonstrating dramatically reduced sphere formation in F siRNA-NFIB-treated and G Dox-treated
stably-expressing miR-212-3p HDMB03 cells. β-actin served as an internal loading control. Data presented as mean ± SD from experiments done in
triplicate and analyzed by Student’s t-test; *p < 0.05; **p < 0.01; ***p < 0.001. Scale bar: 100 μm
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accessibility to pro-metastatic genes. Moreover, c-Myc
was shown to regulate NFIB in SCLC and further contribute to rapid metastases [35].
Metastases at diagnosis and tumor recurrence are cardinal prognostic features contributing to dramatically
increased mortality in group 3 MB [3, 25, 38, 43–45].
MB recurrent tumors, either in the primary or metastatic site, derive from a subpopulation of cancer stem
cells (MBSCs), which can evade current chemotherapeutics and radiation therapy [1]. MBSCs express stemness
markers, such as CD133, CD15, and Sox2, and can possess an inordinate capacity to form aggressive tumors
with increased self-renewal ability, facilitating MB relapse
and rapid demise [48, 50]. In NFIB-silenced and miR212-3p restored group 3 MB cells, we noted decreased
expression of stemness markers, i.e. CD133, Sox2, Oct4,
Nanog, and β-catenin, concurrent with reduced tumor
cell self-renewal capacity as evidenced by sphere-forming
assays. These results introduce miR-212-3p’s role in hampering MBSC maintenance and self-renewal, possibly
through NFIB regulation.
These in vitro findings were translated into an orthotopic mouse model wherein miR-212-3p induction led
to significantly smaller tumors and substantially elevated
survival. Moreover, miR-212-3p-expressing tumors
exhibited decreased staining for Ki-67, c-Myc, and NFIB
and elevated staining for cleaved caspace-3, strengthening our hypothesis of the tumor-suppressive role of miR212 in group 3 MB tumors.

Intriguingly, we have shown EZH2 as an upstream
regulator of miR-212-3p and revealed miR-212-3pmediated destabilization of c-Myc. At the core of these
critical contributors to tumor aggressiveness lies NFIB,
a downstream target of c-Myc (SCLC [35]) and an
inducer of EZH2 (melanoma [13]). Whether NFIB plays
a role in inducing EZH2 in group 3 tumors to epigenetically silence miR-212-3p, in turn stabilizing c-Myc, is an
important mechanism that is being presently evaluated
in detail.

Conclusions
This study has uncovered a novel tumor suppressor gene
in group 3 MB, i.e. miR-212-3p. We have shown expression silencing by histone modifications, as opposed to
hypermethylation. The anti-neoplastic properties of miR212-3p were exhibited by destabilization of c-Myc, cancer
cell arrest at G0/G1 cycle, and robust apoptosis, resulting
in attrition in cancer cell invasiveness and tumor growth
with improved survival in vivo. By targeting NFIB, a wellstudied metastatic driver [8], a regulator of EZH2 [13],
and downstream effector of c-Myc [35], miR-212-3p
decreased cancer cell aggressiveness, stem cell maintenance, and renewal. Our studies provide support for the
use of miRNA-based therapies as a targeted approach to
not only addressing group 3 MB tumor aggressiveness
but also unburdening young patients from the harmful
side‐effects of current cytotoxic therapies.

(See figure on next page.)
Fig. 6 Effect of miR-212-3p expression on in vivo tumorigenicity. A Experimental schema depicting generation of orthotopic group 3 MB mouse
model with stable Dox induction of miR-212-3p. B Bioluminescence images of mice with tumors showing tumor growth on specified days (Day
0, 8 and 16). All images were adjusted to the bioluminescence scale bar shown (Radiance (p/sec/cm2/sr); Color scale—Min: 1.50e4; Max: 1.50e6).
C Graphical quantification of total photon flux (Photons/second) emitted by tumors on indicated days (Day 0, 8 and 16) between mice with or
without Dox treatment, i.e. with or without miR-212-3p expression, respectively. D Kaplan-Meier survival analysis of mice with orthotopic tumors
showing dramatically attenuated survival in control group (without miR-212-3p induction). E Representative histologic images (hematoxylin–
eosin stained paraffin sections) of intra-cranial tumors in control and Dox-treated mice. a and c Area marked (red, 1000 μm) delineates margins
of invading tumor. b and d Magnified images of representative tumor area of a and c (yellow, 100 µm). F Representative images of Ki-67, c-Myc,
NFIB and cleaved caspase-3 staining from control and Dox-treated tumors. G Schematic representation depicting the tumor suppressive actions of
miR-212-3p in group 3 MB. Data presented as mean ± SD from experiments done and analyzed by Student’s t-test; *p < 0.05; **p < 0.01; ***p < 0.001.
Kaplan-Meier survival compared between groups by the Log Rank test (p = 0.0153). Scale bar: 100 μm
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Additional file 1: Supplemental Methods
Additional file 2: Fig. S1. Exploring epigenetic silencing of miR-212-3p in
group 3 MB tumors. (A) Frequency distribution of cytogenetic aberrations (haploinsufficiency of 17p, i17q, c-Myc amplification) in (i) our local
cohort of MB tumors (SHH n=9; group 3 MB n=10; group 4 MB n=16;
Kanchan et al., GSE148390). (ii) Distinguishing features of high-risk tumors
compared between our local cohort (Kanchan et al., GSE148390) and a
larger dataset (Cavalli et al., GSE85217). (B) DNA methylation profile of
local cohort of group 3 (n=6) and group 4 (n=11) MB tumors showing
lack of perturbations to methylation in the promoter region of miR-212-3p
compared to normal pediatric cerebellum (n=4); further demonstrable
in vitro by a lack of expression restoration with de-methylation by 5-AzaC
(5 µM) in HDMB03 cells. (C) Recapitulation of elevated HDAC and EZH2
expression complementing prior in silico data in a large MB meta-dataset
(NC n=291, group 3 MB n=233; Weishaupt et al., GSE124814). (D) RTPCR analysis in pan-HDAC-treated D425 cells (TSA, 100 nM; Belinostat, 1
µM; and Vorinostat, 1 µM) showing elevated expression of miR-212-3p.
RNU6B set as an endogenous control. Western blotting analysis showed
increased acetylated α-tubulin in pan-HDAC inhibitors treated D425 cells.
β-actin served as an internal control. Results presented as mean ± SD
from experiments done in triplicate and analyzed using Student’s t-test (B
and D) or Mann-Whiteny U test (C); *p <0.05, **p <0.01, ***p <0.001. NC,
normal cerebellum; dx, diagnosis.
Additional file 3: Fig. S2. Effect of miR-212-3p expression on SHH MB
cancer cells. (A) RT-PCR analysis showing increased miR-212-3p expression via transient transfection in Daoy cells. Growth restrictive properties
demonstrable by (B) cell proliferation (MTT) and (C) colony formation
assays in miR-212-3p transfected Daoy cells. Data presented as mean
± SD from experiments done in triplicate and analyzed using Student’s
t-test; *p <0.05, **p <0.01, ***p <0.001.
Additional file 4: Fig. S3. Deregulated pathways associated with miR212-3p silencing in group 3 MB. (A) Bubble plot (FunSet plot) representing 12 clusters of significantly enriched GO biological processes. FunSet
employs hypergeometric test to perform the enrichments and additionally uses semantic similarity measure with Aggregate Information Content
(AIC) index to cluster highly similar GO terms [17]. (B) Enriched biological
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pathways associated with miR-212-3p silencing identified using Enrichr
(https://maayanlab.cloud/Enrichr/) [4] highlighting regulation of cell cycle
phase transition as the most enriched pathway in miR-212-3p overexpressed HDMB03 cells
Additional file 5: Table S1. Genes (and associated pathways) enriched
by miR-212-3p expression restoration in HDMB03 cells. Detailed gene
list for selected clusters of significantly enriched GO biological processes
represented in Additional file 4: Fig. S3A. Presented clusters were selected
based on -log10 FDR values with threshold p <0.05.
Additional file 6: Fig. S4. Putative oncogenic targets of miR-212-3p and
their associated pathways in group 3 MB tumors. (A) Expression analysis
by RNA Sequencing of isolated miR-212-3p targets (37 genes) in local
cohort of group 3 MB tumors (pediatric CB n=10; group 3 MB n=7;
Kanchan et al., GSE148390). Those observed to be significantly elevated
in group 3 tumors were the following 14 genes: CCDC71L, CTDSPL2,
EDIL3, GIGYF1, HSBP1, KDM5A, NFIB, NRCAM, PSMA2, SDC2, SEPHS1, TAF4,
TMEM43, and USP9X. (B) Enriched cellular/biological pathways associated
with these targets identified using FunSet tool [17]. (C) Expression of NFIB
across MB subgroups in a large MB meta-dataset (NC n=291; WNT n=118;
SHH MB n=405; group 3 MB n=233; group 4 MB, n=530; Weishaupt et al.,
GSE124814). Box plots (A) represent gene expression (Log2 Transcripts
Per Million) and were analyzed using Mann-Whiteny U test; *p <0.05, **p
<0.01, ***p <0.001. Pathways represented as an inverted bar graph based
on the -log10 FDR values with threshold p <0.05 (red dashed line). CB,
cerebellum; NC, normal cerebellum.
Additional file 7: Table S2. Isolating a strong oncogenic target of miR212-3p. Further analysis of putative miR-212-3p targets by examining
conserved binding sites, confirming elevated expression in 2 independent MB cohorts, and examining effect of high expression on survival. In
the table, ‘x’ denotes inclusion criteria, and ‘-’ denotes no expression data
found in dataset.
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